Other languages Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
1.37 ^USD	+2.24%		-1.44%	-2.84%

Jun. 11	IntelGenx Reports Launch of Sale and Investment Solicitation Process	MT
May. 23	Atai Life Sciences N.V. Announces Board and Supervisory Board Changes	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes	May. 23
Atai Life Sciences Insider Sold Shares Worth $290,502, According to a Recent SEC Filing	May. 20
Atai Life Sciences N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Atai Life Sciences N.V. Announces CEO Changes	May. 15
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	Apr. 24
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	Apr. 17
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 03
Atai Life Sciences Shares Rise Following Maxim Upgrade	Apr. 03
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	Mar. 27
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	Mar. 04
Atai Life Sciences Acquires Stake in Beckley Psytech	Jan. 04
Atai Rallies after Positive Data for Potential PTSD Treatment	Jan. 02
Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)	Jan. 02
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Atai Life Sciences N.V. acquired remaining stake of DemeRx IB, Inc. for $16 million.	Nov. 13
Atai Life Sciences Reports 'Supportive' Results From Phase 1 Study of Oral Transmucosal Film	23-10-02
Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants	23-10-02
IntelGenx Closes First Tranche of Private Placement From Strategic Partner For Aggregate Proceeds of US$3 Million	23-08-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Other languages

Filters